Semaglutide Australia 2026: Research Guide, STEP Trial Data & Reconstitution Protocol

Semaglutide is a long-acting, acylated GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. It is a synthetic analogue of the human GLP-1 hormone, sharing approximately 94% sequence homology with the native peptide. The acylation at position 26 via a C18 fatty diacid linker attached to a modified lysine provides an extended plasma half-life of approximately 7 days, enabling once-weekly administration in research protocols.

Semaglutide is the most extensively studied compound in the GLP-1 receptor agonist class, with data from the SUSTAIN programme (type 2 diabetes outcomes), the STEP programme (obesity), and SELECT (cardiovascular outcomes in non-diabetic individuals with obesity). As of 2026, it remains an active area of research in NASH/MASH, Alzheimer's disease, addiction neuroscience, and heart failure.

Compound identity at a glanceName: Semaglutide · Class: GLP-1 receptor agonist · Structure: 94% homology to native GLP-1, C18 fatty diacid acylation · Half-life: ~7 days · Developer: Novo Nordisk · Approved brands: Ozempic (T2D), Wegovy (obesity) — research-grade supply is distinct from pharmaceutical products

For the full molecular reference — molecular formula, molecular weight, CAS number and the 31-amino-acid sequence — see the Semaglutide molecular profile.

Semaglutide exerts its effects through selective agonism of the GLP-1 receptor, which is expressed in multiple tissues. Unlike short-acting GLP-1 agonists that produce pulsatile receptor stimulation, semaglutide's 7-day half-life provides near-continuous receptor engagement:

The extended half-life is the key pharmacokinetic distinction between semaglutide and earlier GLP-1 agonists. Continuous receptor engagement appears to produce more sustained central appetite suppression than pulsatile dosing, which is reflected in the superior weight loss outcomes versus short-acting compounds in head-to-head trials. For a detailed overview of how GLP-1 receptors in the brain regulate appetite and food reward, see How GLP-1 Peptides Work in the Brain.

Why acylation matters for research stabilityThe C18 fatty diacid chain enables albumin binding, which shields the molecule from DPP-4 degradation and renal clearance. Reconstituted semaglutide in bacteriostatic water benefits from this stability — it remains active for 4–6 weeks at 2–8°C, which is relevant for multi-week research protocols.

Semaglutide has the most comprehensive Phase 3 clinical research dataset of any compound in the GLP-1 class:

STEP 4's discontinuation data is significant for researchers studying maintenance models: participants who stopped semaglutide regained approximately two-thirds of lost weight within 1 year. This supports research hypotheses about chronic receptor engagement being required for sustained metabolic effects — a relevant consideration when comparing compounds with different half-lives.

The SELECT trial (2023) extended cardiovascular research to people without diabetes, demonstrating a 20% MACE reduction in individuals with obesity and prior cardiovascular disease — the first such evidence for any GLP-1 agonist in a non-diabetic population.

For researchers evaluating the three primary GLP-1 class compounds available for Australian research, the following comparison is drawn from separate clinical trials (no direct head-to-head across all three exists):

Semaglutide's primary advantage over newer compounds is the depth of its evidence base. It has completed outcomes trials that tirzepatide and retatrutide are still running. For researchers requiring compounds with established long-term safety profiles from completed Phase 3 data, semaglutide remains the reference standard in the GLP-1 class.

For a breakdown of lean mass versus fat mass lost with each compound — including STEP-1 DXA body composition data — see GLP-1 and lean mass loss: what the clinical data shows.

For a full head-to-head analysis, see the GLP-1 Peptides Comparison Guide.

RetaLABS Semaglutide is supplied as a lyophilised (freeze-dried) powder. Use bacteriostatic water — not sterile water — to extend reconstituted solution stability to 4–6 weeks.

Protocol: Allow vial to reach room temperature. Wipe stopper with alcohol swab. Inject bacteriostatic water slowly along the glass wall — do not direct flow onto the lyophilised cake. Gently swirl until fully dissolved. Do not vortex or shake. Inspect for clarity before use.

Storage: Lyophilised vials at −20°C, protected from light. Reconstituted solution at 2–8°C, use within 4–6 weeks. Do not freeze reconstituted solution or cycle between temperatures. Use the RetaLABS reconstitution calculator for custom concentrations.

The following is drawn from STEP 1 Phase 3 trial data. This information is provided for research context only:

GI adverse events were predominantly mild-to-moderate and most pronounced during the dose escalation phase (typically weeks 1–16 in clinical protocols). Slower escalation schedules were associated with improved tolerability in post-hoc analyses.

Is semaglutide available in Australia for research?

Pharmaceutical semaglutide (Ozempic, Wegovy) is TGA-approved and available by prescription in Australia. Research-grade semaglutide peptide is available from Australian suppliers including RetaLABS for laboratory research purposes — this is legally distinct from pharmaceutical supply.

How does semaglutide compare to tirzepatide and retatrutide?

Semaglutide targets only GLP-1 and achieved 14.9% weight loss at 68 weeks (STEP 1). Tirzepatide adds GIP receptor activity and achieved 20.9% at 72 weeks. Retatrutide adds glucagon receptor activity on top and achieved 24.2% at 48 weeks in Phase 2. Semaglutide has the most complete long-term outcomes evidence of the three.

What concentration should semaglutide be reconstituted to for research?

The working concentration is set by the diluent volume and bounded by the ~3 mL vial capacity, so a 10mg vial gives roughly 3.3–10 mg/mL: adding 1.0 mL gives 10 mg/mL (the standard across the RetaLABS GLP-1 range) and 2.0 mL gives 5 mg/mL for larger, easier-to-measure dose volumes. Use the RetaLABS reconstitution calculator for custom concentrations.

What is SELECT and why does it matter?

SELECT (2023, NEJM) was the first cardiovascular outcomes trial for any GLP-1 agonist in people without diabetes. It enrolled ~17,600 adults with obesity and prior cardiovascular disease and demonstrated a 20% reduction in MACE versus placebo over ~34 months — establishing cardiovascular benefit independent of glycaemic effects.

How long is reconstituted semaglutide stable?

Reconstituted semaglutide in bacteriostatic water stored at 2–8°C is stable for 4–6 weeks. The bacteriostatic agent (benzyl alcohol) prevents microbial growth, extending shelf life compared to sterile water reconstitution (~24–48 hours). Do not freeze reconstituted solution.

What are the main GI side effects seen in semaglutide research?

STEP 1 data reported nausea in 44%, diarrhoea in 30%, vomiting in 24%, and constipation in 24% of the semaglutide group versus 16%, 16%, 6%, and 11% placebo respectively. These were predominantly mild-to-moderate and most common during dose escalation. Discontinuation due to GI adverse events was 4.5% in the semaglutide group.

RetaLABS Semaglutide is research-grade and supplied for laboratory research purposes only. It is not intended for human therapeutic use.

For guidance on assessing research peptide supplier quality, see our Research Peptides Sourcing Guide. For the legal framework governing research peptides in Australia, see our Research Peptides Legal Guide. A downloadable PDF reference summary is also available: Semaglutide 2026 Researcher's Reference Guide.

For the class-level side-effect profile comparing semaglutide with tirzepatide and retatrutide across their published trials, see the GLP-1 Side Effects Cross-Compound Comparison.